<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="52052">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02033330</url>
  </required_header>
  <id_info>
    <org_study_id>Cordiart-PKA-1</org_study_id>
    <nct_id>NCT02033330</nct_id>
  </id_info>
  <brief_title>Assessment of Bioavailability of Phenolics From an Orange Peel Extract</brief_title>
  <official_title>Assessment of Bioavailability of Phenolics From an Orange Peel Extract</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the bioavailability of a specific orange peel extract is tested. The
      composition and morphology of the test product is altered compared to the generic product,
      which is used as a control. Due to intellectual property issues, more information cannot be
      given at this moment. Also the difference in bioavailability between a capsule and a lozenge
      is tested. The hypothesis is that the bioavailability of the altered extract will be
      improved compared to the control.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>plasma concentrations of specific phenolics and their metabolites</measure>
    <time_frame>up to 24 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>urine concentrations of specific phenolics and their metabolites</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Improving Bioavailability</condition>
  <arm_group>
    <arm_group_label>phenolics form orange peel, type 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 dose of 500 mg of phenolics from orange peel, orally ingested</description>
  </arm_group>
  <arm_group>
    <arm_group_label>phenolics from orange peel, type 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 dose of 500 mg of phenolics from orange peel, orally ingested</description>
  </arm_group>
  <arm_group>
    <arm_group_label>phenolics from orange peel, type 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 dose of 500 mg of phenolics from orange peel, orally ingested</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>phenolics form orange peel</intervention_name>
    <arm_group_label>phenolics form orange peel, type 1</arm_group_label>
    <arm_group_label>phenolics from orange peel, type 2</arm_group_label>
    <arm_group_label>phenolics from orange peel, type 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy adults

          -  BMI 18.5 to 25

        Exclusion Criteria:

          -  pregnancy

          -  smoking

          -  alcohol or drug abuse

          -  use of medication

          -  use of nutritional supplements

          -  abnormal liver or kidney function
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chris Van der Grinten, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MUMC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maastricht University Medical Centre</name>
      <address>
        <city>Maastricht</city>
        <zip>6229ER</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 9, 2014</lastchanged_date>
  <firstreceived_date>January 9, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>phenolics</keyword>
  <keyword>orange peel</keyword>
  <keyword>bioavailability</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
